BRP: Stanford's AI-Discovered Peptide That Could Replace Ozempic

The $100 Billion Question

Ozempic changed medicine. In less than five years, Semaglutide went from a niche diabetes drug to a cultural phenomenon — a weekly injection that, for millions of patients, delivered something weight-loss medicine had never reliably produced: real, sustained fat loss. GLP-1 analogues generated $45.3 billion in global revenue in 2024 and are on track to exceed $120 billion by 2030. Novo Nordisk and Eli Lilly are collectively spending more than $80 billion on manufacturing to keep up with demand.

But Semaglutide is far from perfect. Roughly 44% of patients in the STEP clinical trials experienced nausea. Diarrhea, constipation, and vomiting are reported in up to 30% of users. Most unsettling: up to 40% of total weight lost on semaglutide comes from lean muscle mass, not fat — a concern that has prompted growing alarm among geriatricians, sports medicine physicians, and patients who regain weight rapidly after stopping treatment.

Now, a team of Stanford scientists may have found something fundamentally different. Using an artificial intelligence algorithm to scan every protein-coding gene in the human genome, researchers at Stanford Medicine identified a 12-amino-acid peptide called BRP — short for BRINP2-Related Peptide — that suppresses appetite as potently as Semaglutide in animal models, produces fat-specific weight loss, and, critically, appears to cause none of the side effects that drive patients off current GLP-1 drugs.

Published in Nature on March 5, 2025, the discovery represents a potential inflection point in obesity pharmacology: the first credible, naturally-derived, non-incretin weight-loss peptide to emerge from AI-driven research. It is early-stage science — no human trials yet — but the mechanistic rationale and animal data are striking enough to have placed BRP at the center of the next wave of obesity drug development.

This article covers everything known about BRP: how it was found, how it works, what the data show, how it compares to Semaglutide and tirzepatide, and what it means for the $100+ billion race to find better obesity treatments.

What Is BRP?

Origins: From a Brain-Development Gene to a Metabolic Hormone

BRP's parent molecule, BRINP2 (BMP/Retinoic Acid Inducible Neural Specific 2), was previously studied in the context of neurological development — not metabolism. BRINP2 is a secreted glycoprotein expressed in the central nervous system, best known for its role in regulating neural progenitor cell proliferation during embryonic brain development.

What the Stanford team discovered is that BRINP2 is also a prohormone — a precursor protein that, when cleaved by specific enzymes, produces smaller, biologically active peptides. This type of post-translational processing is the same mechanism that produces GLP-1 itself (from proglucagon) and dozens of other hormones. The enzyme responsible is prohormone convertase 1/3 (PC1/3), which cuts prohormones at specific sites — and which has been directly linked to human obesity through genetic studies.

When PC1/3 processes BRINP2, it releases a small 12-amino-acid fragment. That fragment is BRP.

Mechanism: Targeting the Brain's Appetite Command Center

The key distinction between BRP and every GLP-1-class drug currently on the market comes down to where each molecule acts.

Semaglutide (Ozempic, Wegovy) works by binding to GLP-1 receptors, which are distributed throughout the body: the gut, pancreas, heart, kidneys, and brain. This broad receptor distribution is why Semaglutide produces such a wide range of effects — blood sugar reduction, delayed gastric emptying, appetite suppression, and cardiovascular protection all stem from the same receptor interaction. It also explains the side effects: slowed gastric emptying causes nausea; gut and pancreatic receptor activation drives GI distress.

BRP appears to act specifically in the hypothalamus — the brain's appetite-regulation hub — without engaging GLP-1 receptors, leptin receptors, or melanocortin 4 receptors (MC4R). As Dr. Svensson explained in the Stanford Medicine press release: "The receptors targeted by Semaglutide are found in the brain but also in the gut, pancreas and other tissues. That's why Ozempic has widespread effects including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism."

At the cellular level, BRP activates the cAMP–PKA–CREB–FOS signaling cascade in hypothalamic neurons — a pathway associated with appetite suppression and metabolic regulation. The expression of FOS protein, a well-established marker of neuronal activation, was confirmed in hypothalamic tissue from BRP-treated animals. Notably, BRP did not activate the brainstem circuits responsible for nausea and aversion — the same circuits that GLP-1 drugs engage, producing the characteristic queasiness of Ozempic treatment.

At a Glance: BRP Key Facts

How Was BRP Discovered? The AI Peptide Predictor

The Problem: Most Peptide Hormones Are Unknown

The human genome encodes roughly 20,000 protein-coding genes — but the vast majority of biologically active peptides derived from those genes remain uncharacterized. The body's "peptidome" is largely unmapped. Traditional peptide discovery relies on laborious biochemical purification, bioassays, and serendipitous findings — a process that has yielded important hormones like insulin, Glucagon, and GLP-1, but leaves thousands of potential signaling molecules undiscovered.

Katrin Svensson's laboratory at Stanford Medicine — officially the Laboratory of Metabolic Regulation at the Stanford Diabetes Research Center — was founded on the premise that this gap represents one of the largest untapped opportunities in pharmacology. "My lab is driven by the idea that there are many peptide hormones that we haven't yet discovered," Svensson has stated publicly. Her co-investigator on the BRP study, postdoctoral researcher Laetitia Coassolo, PhD, led the computational and experimental work.

The Algorithm: Peptide Predictor

To systematically mine the genome for undiscovered peptide hormones, the Stanford team developed a bioinformatics tool called Peptide Predictor. The algorithm works as follows:

1. Full genome scan — Peptide Predictor screened all 20,000 human protein-coding genes, looking specifically for proteins with signal peptides (indicating secretion outside the cell) and multiple PC1/3 cleavage consensus sequences.
2. Prohormone shortlist — The system identified 373 prohormone candidates — proteins structurally capable of producing bioactive peptide fragments after enzymatic processing.
3. Peptide prediction — From those 373 prohormones, the algorithm predicted 2,683 possible peptide fragments that could result from PC1/3 cleavage.
4. Experimental validation — Researchers selected 100 predicted peptides — including GLP-1 as a positive control — and tested each on cultured hypothalamic neurons, measuring neuronal activation via FOS expression and cAMP signaling.

As Dr. Svensson noted: "The algorithm was absolutely key to our findings." Without it, the BRP peptide — embedded inside a gene previously known only for developmental neurology — would have been invisible to conventional screening approaches.

The Discovery Moment

When the 100 predicted peptides were tested on lab-grown hypothalamic neurons, most produced modest or no activity. GLP-1, as expected, significantly increased neuronal activity. But one peptide stood out: a 12-amino-acid fragment produced neuronal activation tenfold greater than control cells — and significantly stronger than GLP-1 itself. That peptide was BRP.

The 10x potency advantage in neuronal activation is striking. GLP-1 agonists already represent the most effective pharmacological approach to appetite suppression ever developed. A molecule that outperforms GLP-1 in direct neuronal potency — while acting through an entirely different receptor and pathway — represents a genuinely novel class of anti-obesity compound.

BRP vs. Semaglutide: A Head-to-Head Comparison

Mechanistically, BRP and semaglutide are fundamentally different molecules pursuing the same outcome through different routes. The comparison below uses current published data; BRP data are preclinical only.

Note: BRP data are from animal models only. Direct human comparisons cannot yet be made. Semaglutide efficacy data from STEP 1–4 and SUSTAIN clinical trial programs.

Animal Study Results: What the Data Actually Show

The BRP preclinical program tested the peptide in two species — laboratory mice and Göttingen minipigs, the latter specifically chosen because minipig metabolic physiology and feeding behavior more closely mirror human biology than rodent models do. This cross-species validation strengthens the translational argument for BRP considerably.

Acute Appetite Suppression

In lean C57BL/6 male mice and minipigs, a single intraperitoneal injection of BRP before feeding reduced food consumption by up to 50% within one hour. The effect was rapid-onset and clean — no signs of malaise, nausea-related behaviors, reduced locomotor activity, elevated anxiety, or changes in water intake. The researchers specifically monitored for conditioned taste aversion (a standard preclinical nausea proxy) and found none.

This is meaningful context. GLP-1 agonists do suppress appetite, but they also activate the area postrema — the brain's "nausea center" — which is a mechanistic consequence of their widespread receptor expression. BRP's hypothalamus-specific action appears to sidestep this entirely.

Chronic Weight Loss in Obese Mice

In diet-induced obese mice, daily BRP administration over 14 days produced an average weight loss of 3 grams, primarily from fat. Control mice fed the same high-fat diet gained approximately 3 grams over the same period — making the net metabolic divergence roughly 6 grams between groups. At typical obese mouse weights of 40–50 grams, this represents approximately 12–15% body weight difference.

The weight lost was predominantly adipose tissue. Histological analysis confirmed:

• Reduced fat accumulation in white adipose tissue (WAT)
• Improved metabolic function in liver and skeletal muscle
• Preservation of lean (muscle) mass — in stark contrast to Semaglutide's lean-mass losses
• Improved glucose tolerance and insulin sensitivity

Additionally, none of the monitored behavioral or physiological markers suggested systemic stress: fecal output was normal (ruling out diarrhea/constipation), activity levels were unchanged, and anxiety-like behaviors were absent.

Minipig Validation

The minipig results replicated the appetite-suppression findings. BRP reduced food intake in minipigs without affecting overall energy expenditure — suggesting the effect is satiety-based (eating less) rather than metabolic-rate-based (burning more). This cross-species consistency is a key checkpoint before human trials: if an effect doesn't hold in at least one large-animal model, the probability of human translation drops dramatically.

"Nothing we've tested before has compared to Semaglutide's ability to decrease appetite and body weight. We are very eager to learn if it is safe and effective in humans."

— Katrin Svensson, PhD, Assistant Professor of Pathology, Stanford Medicine

Why the GLP-1 Market Desperately Needs Competition

A Market Built on Unmet Demand

The GLP-1 market's rapid ascent is not a pharmaceutical anomaly — it reflects the scale of the obesity epidemic and the historic absence of effective, tolerable long-term treatments. With analysts projecting the obesity drug market will approach $100 billion by 2030, Novo Nordisk and Eli Lilly are the two dominant players — and both have bet their near-term futures on GLP-1-class drugs.

The competitive dynamics are extraordinary. Novo Nordisk invested $33 billion in manufacturing from 2020–2024 alone, and its revenue doubled from $21 billion to $44 billion over that period — driven almost entirely by Ozempic and Wegovy. Eli Lilly, meanwhile, committed $50 billion to manufacturing and saw its combined Mounjaro/Zepbound revenues hit $36.5 billion in 2025 (56% of total company revenue), positioning it as arguably the world's most valuable pharmaceutical company.

But this duopoly faces structural pressure. Compounded Semaglutide flooded U.S. markets in 2024–2025 before FDA enforcement actions tightened access. Patent cliffs are approaching. And most fundamentally, GLP-1 drugs have a discontinuation problem: when patients stop taking them — due to cost, side effects, or supply issues — they typically regain all lost weight, plus more, because the underlying metabolic pathways are unchanged.

The Side Effect Problem Isn't Small

The clinical trial data on Semaglutide side effects are sobering:

• Nausea: reported by 43.9% of patients on the 2.4 mg Wegovy dose in STEP 1–3 trials, vs. 16.1% on placebo
• Diarrhea: up to 30% of patients taking Wegovy for weight loss
• Constipation: commonly reported, particularly early in treatment
• Muscle loss: up to 40% of total weight lost on semaglutide is lean mass — a ratio that raises long-term concerns about sarcopenia, frailty, and metabolic rebound
• Pancreatitis: rare but serious; FDA boxed warning for thyroid C-cell tumors

The muscle loss issue is particularly consequential for older patients. Researchers at UNC Medicine have noted that losing muscle mass and strength can lead to sarcopenia, functional decline, disability, and nursing home placement — outcomes that could offset obesity benefits for patients over 65.

Even among younger patients, losing one-third of weight as muscle — then regaining it as fat when stopping treatment — creates a metabolic profile that may actually worsen body composition over time. The search for an agent that achieves fat-specific weight loss, without muscle loss or GI side effects, is not merely academic. It represents the most important unsolved problem in obesity pharmacology.

The Race to Next-Generation Treatments

Both Novo Nordisk and Eli Lilly recognize that GLP-1 monotherapy is not the endpoint. In 2026 alone, oral GLP-1 formulations from both companies entered the market: the FDA approved Eli Lilly's orforglipron (brand name Foundayo) on April 1, 2026, making it the second approved oral GLP-1 drug behind Novo's oral Wegovy. Access and convenience are real differentiators — but the fundamental mechanism remains the same.

BRP, if it survives human trials, would represent a different category entirely: the first non-incretin, hypothalamus-specific anti-obesity peptide. Roche's $2.7 billion acquisition of Carmot Therapeutics (developer of obesity peptides) in 2024 signals that big pharma is actively preparing for the post-GLP-1 era. BRP could be the first molecule from that era to reach clinical development.

The Pipeline: Next-Generation Weight Loss Treatments

BRP is one of several emerging approaches that could reshape obesity treatment over the next five to ten years. Below is a summary of the most advanced pipeline candidates, alongside BRP's current position.

Why the Pipeline Matters

The drugs above represent iterative improvements within the GLP-1 framework — each adding receptor targets (Glucagon, GIP, amylin) to squeeze additional efficacy from the incretin system. Retatrutide's 28.7% weight loss is genuinely remarkable; it may bring pharmacological weight loss into territory previously achievable only through bariatric surgery.

But all of them share GLP-1's fundamental architecture: they work by mimicking or amplifying incretin signaling, which means they carry the same inherent potential for nausea, gastric effects, and variable tolerability. BRP is the only molecule in serious preclinical development that operates through an entirely independent pathway — which is why even researchers who are cautious about the preclinical-to-human translation gap take the finding seriously.

For reference, other metabolic peptides like MOTS-C and AOD-9604 have been studied for their metabolic properties, but have not demonstrated the central appetite-suppression mechanism or cross-species consistency that BRP has shown in peer-reviewed research.

What Comes Next for BRP?

Finding the Receptor: The Critical Unknown

The most significant scientific gap in the BRP story is the receptor identification problem. The Stanford team confirmed that BRP does not act through GLP-1R, leptin receptors, or MC4R — but the molecule that BRP actually binds to in the hypothalamus remains unknown. This is not unusual at this stage of peptide research (GLP-1 itself was discovered before its receptor was fully characterized), but it is a prerequisite for therapeutic development.

Receptor identification will do three things: enable rational drug design (modifying BRP's structure for longer half-life and oral bioavailability), clarify the safety profile (by mapping what else the receptor does in the body), and potentially reveal whether there are existing drugs that act on the same target. Svensson's lab has stated this is a primary current focus.

The Half-Life Challenge

Small peptides like BRP are metabolically unstable — they are rapidly cleaved by circulating proteases and cleared by the kidneys. This is not a unique problem: GLP-1 itself has a half-life of only 1–2 minutes in the bloodstream, which is why Semaglutide requires fatty acid modification and albumin-binding chemistry to achieve its once-weekly dosing profile.

The same engineering approaches — lipid conjugation, PEGylation, amino acid substitution, or fusion with albumin-binding peptides — will likely be needed to extend BRP's half-life from minutes to days. This is a well-characterized pharmaceutical chemistry problem with established solutions. It does not represent a fundamental obstacle to development, but it does mean that the "BRP" in eventual human trials will likely be a modified analog, not the identical 12-amino-acid native sequence.

The Clinical Path: Company Formation and Human Trials

Dr. Svensson has co-founded a company to advance BRP toward clinical trials, following the standard Stanford technology transfer pathway. The company has not yet been named publicly. Based on typical preclinical-to-Phase 1 timelines — receptor identification, lead optimization, toxicology studies, IND filing — a first-in-human study is realistically 3–5 years away, placing initial human data in the 2027–2030 range at the earliest.

The global obesity pipeline currently includes 48 Phase III candidates, 109 Phase II candidates, and 155 Phase I candidates. BRP would enter this pipeline as a Phase I candidate — but with a differentiated mechanism that no current clinical-stage compound shares. In a crowded field, mechanism differentiation is the most durable competitive advantage.

Investment and Industry Context

The GLP-1 market's financial trajectory has attracted capital to obesity drug development at an unprecedented scale. Roche acquired Carmot Therapeutics — a developer of novel obesity peptides — for $2.7 billion in 2024. The broader peptide therapeutics market is projected to nearly double by 2033, driven significantly by metabolic disease applications. A Stanford-backed non-incretin peptide with a novel mechanism and a peer-reviewed Nature publication will attract serious biotech and pharma attention — the question is not whether BRP will be funded, but whether the biology will hold in humans.

Frequently Asked Questions

Sources & References

1. Coassolo L, et al. Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide. Nature. 2025;641(8061):192–201. doi:10.1038/s41586-025-08683-y
2. Stanford Diabetes Research Center. Breakthrough Study led by SDRC Investigator Katrin Svensson Identifies Ozempic Rival For Weight Loss Without The Side Effects. March 5, 2025. sdrc.stanford.edu
3. ScienceDaily. Stanford scientists discover "natural Ozempic" without side effects. April 12, 2026. sciencedaily.com
4. Sidharthan C. Stanford Researchers Find a Molecule That Rivals Ozempic in Weight Loss. AZoLifeSciences, March 17, 2025. azolifesciences.com
5. Newsweek. New Discovery Promises Weight Loss Without Ozempic's Side Effects. March 7, 2025. newsweek.com
6. PubMed. Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide. PMID: 40044869
7. GLP-1 Analogues Strategic Business Report 2026. Yahoo Finance / Research and Markets. March 3, 2026. Yahoo Finance
8. Grand View Research. GLP-1 Agonists Weight Loss Drugs Market Report 2030. grandviewresearch.com
9. CNBC. 2026 is the year of obesity pills from Novo Nordisk, Eli Lilly. January 10, 2026. cnbc.com
10. Lola Health. Retatrutide Clinical Trials | Phase 3 TRIUMPH Results. February 23, 2026. lolahealth.com
11. Clinical Trials Arena. Lilly's triple G agonist boasts 28.7% weight loss in Phase III trial. December 12, 2025. clinicaltrialsarena.com
12. Amgen. Results From Amgen's Phase 2 Obesity Study of Monthly MariTide Presented at ADA 85th Scientific Sessions. June 23, 2025. amgen.com
13. Fierce Biotech. Novo Nordisk plots phase 3 trials for next-gen obesity asset Amycretin. June 13, 2025. fiercebiotech.com
14. Caroline Fife, MD. FDA Grants Speedy Approval to Eli Lilly's Oral GLP-1 RA Drug for Obesity. April 6, 2026. carolinefifemd.com
15. PMC / Current Reviews in Musculoskeletal Medicine. The Effects of GLP-1 Agonists on Musculoskeletal Health. May 2025. pmc.ncbi.nlm.nih.gov
16. GoodRx. 19 Ozempic and Wegovy Side Effects You Should Know About. goodrx.com
17. UNC Department of Medicine. Why are GLP-1 Drugs Like Ozempic Risky for Older Adults? June 2024. med.unc.edu

Explore Related Peptide Profiles

PeptideKnow profiles each peptide referenced above, with mechanism of action, dosage data, research summaries, and safety information:

For background on peptide pharmacology, start with our Beginner's Guide to Peptides or explore the full PeptideKnow database.